Ranbaxy Pharmaceuticals on Tuesday launched the authorised generic cevimeline hydrochloride 30 mg capsules in the US market under an agreement with Daiichi Sankyo.
56218
Ranbaxy launches cevimeline hydrochloride capsules in US market
107899
First effective treatment for most common form of Hepatitis C launched
89032
Abiomed's to begin selling ``world's smallest heart pump'' in US
108482
Regulatory, commercial considerations are the primary drivers for biosimilar development
78472
Cholera vaccine licensed
77990
Daiichi Sankyo to support and co-sponsor phase 1 clinical study
113336
Reasons to use prescription drug generic brands
67539
YM BioSciences reports nimotuzumab approved for marketing in Mexico
131807
Drug delivery markets:
73265
Ashland to launch UV-absorbing ingredient bemotrizinol in US
6492
Eisai launches epilepsy drug in UK
61600
Ranbaxy has target of Rs 550:
141542
New Pharmacy opens in Gowanda
20188
Ranbaxy gains 4.8%;
174711
FDA approves obesity drug Belviq
41423
Dainippon Sumitomo Pharma to buy US bio-venture
140704
Amgen licenses molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.